Advertisement
Home »

Thiopurines have no impact on outcomes of Crohn’s disease patients beyond 12 months of maintenance treatment with infliximab.

Nov 20, 2023

ABOUT THE EXPERTS

  • Paula Sousa

    Department of Gastroenterology, Viseu-Tondela Hospital Centre, Viseu, Portugal.

    Marta Patita

    Department of Gastroenterology, Garcia da Orta Hospital, Almada, Portugal.

    Bruno Arroja

    Department of Gastroenterology, Braga Hospital, Braga, Portugal.

    Paula Lago

    Department of Gastroenterology, Porto Hospital University Centre, Porto, Portugal.

    Isadora Rosa

    Department of Gastroenterology, IPOLFG, EPE, Lisbon, Portugal.

    Helena Tavares de Sousa

    Department of Gastroenterology, Algarve Hospital University Centre – Portimão Unit, Portimão, Portugal; ABC – Algarve Biomedical Center, University of Algarve, Faro, Portugal.

    Paula Ministro

    Department of Gastroenterology, Viseu-Tondela Hospital Centre, Viseu, Portugal.

    Irina Mocanu

    Department of Gastroenterology, Garcia da Orta Hospital, Almada, Portugal.

    Ana Vieira

    Department of Gastroenterology, Garcia da Orta Hospital, Almada, Portugal.

    Joana Castela

    Department of Gastroenterology, IPOLFG, EPE, Lisbon, Portugal.

    Joana Moleiro

    Department of Gastroenterology, IPOLFG, EPE, Lisbon, Portugal.

    Joana Roseira

    Department of Gastroenterology, Algarve Hospital University Centre – Portimão Unit, Portimão, Portugal; ABC – Algarve Biomedical Center, University of Algarve, Faro, Portugal.

    Eugenia Cancela

    Department of Gastroenterology, Viseu-Tondela Hospital Centre, Viseu, Portugal.

    Francisco Portela

    Department of Gastroenterology, Coimbra Hospital University Centre, Coimbra, Portugal.

    Luis Correia

    Department of Gastroenterology, Northern Lisbon University Hospital Centre, Lisbon, Portugal.

    Mafalda Santiago

    Center for Health Technology and Services Research (CINTESIS), Porto, Portugal; Portuguese Group of Studies in Inflammatory Bowel Disease (Grupo de Estudos da Doença Inflamatória Intestinal – GEDII), Porto, Portugal.

    Sandra Dias

    Portuguese Group of Studies in Inflammatory Bowel Disease (Grupo de Estudos da Doença Inflamatória Intestinal – GEDII), Porto, Portugal.

    Catarina Alves

    Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.

    Joana Afonso

    Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.

    Claudia Camila Dias

    Knowledge Management Unit, Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal; CINTESIS@RISE, Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal.

    Fernando Magro

    Center for Health Technology and Services Research (CINTESIS), Porto, Portugal; Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal; CINTESIS@RISE, Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal; Department of Gastroenterology, São João Hospital University Centre, Porto, Portugal; Unidade de Farmacologia Clínica, São João Hospital University Centre, Porto, Portugal. Electronic address: fm@med.up.pt.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisementt